Medicago’s Plant-Based COVID Shot Begins Phase 3 Trial With GlaxoSmithKline

March 16, 2021 12:02 PM EDT | By Shreya Biswas
 Medicago’s Plant-Based COVID Shot Begins Phase 3 Trial With GlaxoSmithKline

Source: Aedka Studio, Shutterstock

Summary

  • Canadian biopharmaceutical firm Medicago Inc announced on Tuesday that its plant-derived COVID-19 vaccine candidate has been ushered into Phase 3 clinical trials.
  • Medicago said that its shot will be tested in combination with British company GlaxoSmithKline’s COVID-19 adjuvant as part of the ongoing Phase 2/3 study.
  • The Canadian and US regulatory authorities have reportedly approved the Quebec-based company’s application to enroll candidates in its Phase 3 trials based on positive interim results of its Phase 2 study.

Canadian biopharmaceutical firm Medicago Inc announced on Tuesday, March 16, that its plant-derived COVID-19 vaccine candidate has been ushered into Phase 3 clinical trials.

Medicago said that its shot will be tested in combination with British company GlaxoSmithKline’s (LON:GSK) COVID-19 adjuvant as part of the ongoing Phase 2/3 study.

Let’s find out more about Medicago’s late-stage trials.

 

Medicago COVID-19 Vaccine Candidates Phase 3 Trials – Key Insights


Medicago, a plant-based biotech researcher, became a privately held company in September 2013. Its shares, formerly listed under the ticker of ‘MDG’, were removed from the Toronto Stock Exchange in 2013 following its transition to the private sector.

The Canadian and US regulatory authorities have reportedly approved the Quebec-based company’s application to enroll candidates in its Phase 3 trials based on positive interim results of its Phase 2 study.

Medicago said that the Phase 3 portion of the trials, which will be randomized and observer-blinded, will review the efficacy and safety parameters of the adjuvanted CoVLP formulation is comparison to placebos.

©Kalkine Group 2020

 

The study will be conducted with up to 30,000 subjects in total, the initial stage of which will see healthy adults in the age group of 18 years to 65 years. Later on, the study will focus on elderly people above the age of 65 years and adults who live with comorbidities.

The biotech firm also said that the trial will be conducted in 10 countries following required regulatory approvals.

Medicago has also started working on a feasibility study for a vaccine candidate focused on the emerging mutant variants of the COVID-19 disease.

 

What Do We Know About Medicago’s Plant-Based COVID-19 Vaccine Candidate?


A vaccine is generally developed by using a non-infectious version of the target virus which, when administered, triggers the body into building an immune system to fight the real virus.

©Kalkine Group 2020

 

While such non-contagious particles are typically developed in labs using live viruses, Medicago came up with a way to use live plants as bioreactors to create the Coronavirus-like Particles (CoVLPs). It is said to have successfully produced a CoVLP to combat the COVID-19 virus, SARS-CoV-2, in early March last year.

Medicago's plant-based COVID-19 vaccine candidate, which comes with a booster from  GlaxoSmithKline, is required to be administered in two doses 21 days apart.

The US Food and Drug Administration (FDA) greenlit Medicago’s vaccine candidate, in combination with GlaxoSmithKline’s pandemic adjuvant, for a Fast Track designation on February 17.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.